Retrospective analysis of clinical pregnancy outcomes in patients with chromosome 9 inversion

Purpose To investigate whether Preimplantation genetic testing for aneuploidy (PGT-A) improves clinical outcomes among couples with pericentric inversion of chromosome 9. Methods This retrospective analysis included data from 340 couples with inversion 9 from 2018 to 2022. Clinical outcomes were compared between the PGT-A group (n = 31) and the conventional in vitro fertilization (IVF)/ intracytoplasmic sperm injection (ICSI) group (n = 309). Result(s): Compared with other autosomes, chromosome 9 did not have a greater frequency of aberrations in embryos (0.062% vs. 0.074%, p > 0.05). The cumulative live birth rate (CLBR) per ovarian stimulation cycle and cancellation rate were comparable between the PGT-A group and the IVF/ICSI group (OR 1.630, 95% CI 0.588–4.516; OR 0.271, 0.057–1.281, respectively). However, the PGT group presented significantly fewer embryo transfers (ETs) than the control group did (1.06 vs. 1.31, OR 0.628, 95% CI 0.468–0.843). The LBRs per embryo transfer were similar between the PGT group and the IVF/ICSI group at the first single blastocyst transfer cycle (OR 2.298, 95% CI 0.550–9.595), as were the clinical pregnancy rates (OR 1.036, 95% CI 0.223–4.820) and the pregnancy loss rates (OR 0.161, 95% CI 0.017–1.571). Conclusion(s): Clinical outcomes among inversion 9 carriers were similar between the PGT and IVF/ICSI groups. However, PGT can decrease the number of ETs required to reach a live birth for inversion 9 carriers. Based on the oocyte utilization rates, PGT is not recommended for inversion 9 carriers.